Nucleos(t)ide analogues (NA) are effective in suppressing hepatitis B virus (HBV) replication, but most patients require long-term treatment. This study aimed to investigate switching to peginterferon as a strategy to stop NA. Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients who developed HBeAg seroconversion during NA treatment were studied. All patients received open-label peginterferon alfa-2a 180 μg/wk for 48 weeks, and NA was stopped at week 4 of peginterferon treatment. The primary endpoint was sustained response, which was defined as negative HBeAg, positive anti-HBe and HBV DNA <2000 IU/mL at week 72. Other secondary endpoints including HBsAg loss at week 72 were also studied. Forty-one patients treated with entecavir for 56 ± 23 months were recruited. Sustained response was achieved in 30 patients (73%, 95% confidence interval 58%-84%). At week 72, 31 (76%) patients had HBeAg seroconversion, 56 (23%) patients had undetectable HBV DNA, 31 (76%) patients had normal ALT, and 6 patients (15%) had HBsAg loss. Baseline HBsAg level was the best predictor for both sustained response and HBsAg loss; the best HBsAg cut-off for sustained response was <1500 IU/mL and that for HBsAg loss was <500 IU/mL by receiver operating characteristic curve analysis. Twenty-two of 25 (88%) patients with baseline HBsAg <1500 IU/mL had sustained response. Five of 10 (50%) patients with baseline HBsAg <500 IU/mL developed HBsAg loss. Switching to peginterferon can be considered as a treatment option in NA-treated patients with HBeAg seroconversion, particularly among those with lower HBsAg levels.
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Summary
Nucleos(t)ide analogues (NA) are effective in suppressing hepatitis B virus (HBV) replication, but most patients require long-term treatment. This study aimed to investigate switching to peginterferon as a strategy to stop NA. Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients who developed HBeAg seroconversion during NA treatment were studied. All patients received open-label peginterferon alfa-2a 180 μg/wk for 48 weeks, and NA was stopped at week 4 of peginterferon treatment. The primary endpoint was sustained response, which was defined as negative HBeAg, positive anti-HBe and HBV DNA <2000 IU/mL at week 72. Other secondary endpoints including HBsAg loss at week 72 were also studied. Forty-one patients treated with entecavir for 56 ± 23 months were recruited. Sustained response was achieved in 30 patients (73%, 95% confidence interval 58%-84%). At week 72, 31 (76%) patients had HBeAg seroconversion, 56 (23%) patients had undetectable HBV DNA, 31 (76%) patients had normal ALT, and 6 patients (15%) had HBsAg loss. Baseline HBsAg level was the best predictor for both sustained response and HBsAg loss; the best HBsAg cut-off for sustained response was <1500 IU/mL and that for HBsAg loss was <500 IU/mL by receiver operating characteristic curve analysis. Twenty-two of 25 (88%) patients with baseline HBsAg <1500 IU/mL had sustained response. Five of 10 (50%) patients with baseline HBsAg <500 IU/mL developed HBsAg loss. Switching to peginterferon can be considered as a treatment option in NA-treated patients with HBeAg seroconversion, particularly among those with lower HBsAg levels.
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| INTRODUC TI ON
Chronic hepatitis B is the commonest cause of liver cirrhosis and hepatocellular carcinoma in most Asian countries.
1 Treatment with interferon and nucleos(t)ide analogues (NA) can reduce the risk of hepatocellular carcinoma. 2 NA is very effective in suppressing viral replication, which can be translated to reduced liver-related complications. 3, 4 However, most patients require long-term NA treatment, and premature drug cessation may lead to hepatitis relapse.
Although NA has generally good safety profile, 5, 6 long-term treatment still has the problems of drug adherence and cost. 
| MATERIAL S AND ME THODS

| Study design
| Patient population
| Study endpoints
The primary endpoint was sustained response, which was de- 
| Assays
Hepatitis B virus DNA was quantified by TaqMan real-time polymerase chain reaction assay as described previously. 
| Statistical analysis
Efficacy of treatment was analysed by intent-to-treat analysis. All patients who received a single dose of injection of peginterferon were included in the intent-to-treat analysis. All patients who could not complete per-protocol treatment or had NA restarted were regarded as treatment failure. Baseline and on-treatment factors predicting sustained response and HBsAg loss at week 24 post-treatment were analysed by logistic regression analysis. Best cut-off values of predicting parameters were obtained by Youden index using receiver operating characteristics curve analysis.
When the study protocol was designed, only data on stopping lamivudine were available in the literature. Based on previous studies on stopping lamivudine, approximately 30% of patients developed virologic relapse even lamivudine was stopped after HBeAg seroconversion. [19] [20] [21] [22] We assumed that sustained response to peginterferon would not be inferior to that after stopping lamivudine; that is, sustained response rate should be at least 70%. To achieve an estimated half width confidence interval (CI) of 10%, 81 patients would be required. However, due to difficult patient recruitment of this study, the study was prematurely stopped after 41 patients were recruited in 4 years.
| Role of the funding source
This study was supported by an unrestricted grant from Roche Pharmaceutical. Roche Pharmaceutical also supported the study medication of this study. The funding source had no role in study design; conduction of clinical study; collection, management, interpretation and analysis of data; writing of manuscript; or the decision to submit the manuscript for publication. The corresponding author has full access to all the data and has the final responsibility for decision to submit for publication.
| RE SULTS
| Baseline characteristics
From August 2013 to June 2016, 41 patients were recruited into the study ( Figure 1 ). The clinical characteristics are shown in Table 1 . All patients were on entecavir, with negative HBeAg, positive anti-HBe, undetectable HBV DNA and normal ALT at baseline of peginterferon treatment. All patients had compensated liver disease.
| Efficacy
Primary endpoint, sustained response with negative HBeAg, positive anti-HBe and HBV DNA <2000 IU/mL at week 72 were achieved in 30 of the 41 patients (73%, 95% CI 58%-84%). All 6 patients (15%, 95% CI 7%-28%) who had HBsAg loss at week 48
remained HBsAg negative at week 72, and all of them had undetectable HBV DNA and normal ALT.
If we exclude the 4 patients who prematurely withdrew peginterferon treatment for per-protocol analysis, the sustained response rate was 81% (30 of 37 patients) and HBsAg loss rate was 16% (6 of 37 patients).
| Factors associated with responses
| Predictors for sustained response
Lower HBsAg level at baseline was the strongest predictor of sustained response, with an odds ratio of 0.12 (95% CI 0.02-0.77) ( Table 2 ). Lower HBsAg level at week 24 of peginterferon was also associated with a higher chance of sustained response. Other factors including age, gender, baseline ALT and ALT flare during peginterferon treatment were not associated with sustained response. The area under ROC curve of baseline HBsAg for sustained response was 0.75 (95% CI 0.58-0.92) (Figure 2A ). The best cut-off baseline HBsAg was 1500 IU/mL, which has a sensitivity of 73% and specificity of 77% to predict sustained response. Twenty-five of 41 (61%) patients had baseline HBsAg <1500 IU/mL, among whom 22 (88%) patients could achieve sustained response (Table 4) .
Patients who have sustained response also tend to have lower HBsAg levels at week 12 and week 24 ( Table 2 ). The kinetics of HBsAg during and after treatment among sustained responders and non-responders are shown in Figure 3A .
| Predictors for HBsAg loss
Lower HBsAg at baseline was again a strong predictor of HBsAg loss at week 72, with an odds ratio of 0.08 (95% CI 0.01-0.62) ( Table 3 ). ( Figure 2B ). The best cut-off baseline HBsAg was 500 IU/mL, which has a sensitivity of 86% and specificity of 83% to predict HBsAg loss at week 72. Ten of 41 (24%) patients had baseline HBsAg <500 IU/ mL, among whom 5 (50%) patients developed HBsAg loss (Table 4) .
Patients who have HBsAg loss also tend to have lower HBsAg levels at week 12 and week 24 ( Table 3 ). The kinetics of HBsAg 
| Safety
Adverse events are summarized in Table 5 
| D ISCUSS I ON
In did not yield superior results as compared to peginterferon monotherapy. [23] [24] [25] In a more recent clinical trial, combining peginterferon with tenofovir disoproxil fumarate for 1 year was shown to associate with a higher cumulative rate of HBsAg loss (9.1%) vs peginterferon monotherapy (2.8%) at 24-week post-treatment. 26 Although the rate of HBsAg loss was still low with peginterferon and tenofovir combination, it re-ignites the interest to investigate the possibility of this combination strategy as a cure of chronic hepatitis B.
Hepatitis B e antigen seroconversion is regarded as an initial step of immune clearance in the natural history of chronic hepatitis B.
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All regional guidelines do not recommend treatment for non-cirrhotic HBsAg, hepatitis B surface antigen. [28] [29] [30] [31] In the OSST study which studied patients with low HBeAg titre or HBeAg loss on entecavir switching to peginterferon in China, 7 (73%) of the 11 patients who had HBeAg seroconversion at the end of peginterferon treatment had HBeAg seroconversion sustained at 1-year post-treatment follow-up. 16 In the present study in Hong Kong, all 41 patients had HBeAg seroconversion at the start of treatment, and 73% of them remained HBeAg negative and anti-HBe positive with HBV DNA <2000 IU/mL 24-week post-treatment. Unfortunately, both studies did not include a control arm of stopping NA. In a systematic review of predominant retrospective cohort studies with heterogeneous patient population, the estimated probability of virologic response as defined as HBeAg seroconversion and HBV DNA <2000 IU/mL post-treatment was 71.2%.
TA B L E 5 Adverse events reported by patients in the study
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As an HBsAg loss rate of 15% is still low after switching from NA to peginterferon, it is reasonable to select a subgroup of patients who have a higher chance of response for the switch therapy. Because production of HBsAg is not directly affected by NA, the level of HBsAg is a reasonable indirect marker to reflect immune control of transcriptional activities of the covalently closed circular DNA inside the liver. 32 Low HBsAg has been consistently found to be a baseline predictor of response to peginterferon among NA-treated patients. In studies in China, HBeAg-negative patients with baseline HBsAg <1500 IU/mL have 22%-25% chance of losing
HBsAg after 1 year of peginterferon treatment. 15, 17 In this study in Hong Kong, patients with baseline HBsAg <1500 IU/mL have 20% chance of developing HBsAg loss, whereas baseline HBsAg <500 IU/ mL is the best predictor for HBsAg loss (50% This study has a few key limitations. First, difficult patient recruitment has rendered our sample size fall short of the estimated.
Only 41 eligible patients could be recruited from 5 centres in 3 years.
Although the point estimate of sustained response (73%) is in concordance with the estimated, the 95% CI is a bit wider than 10%; the current half width 95% CI is 11%-15%. Second, we did not include a Although we believe that HBeAg seroconversion on NA is a better starting point for peginterferon treatment than low HBeAg titre or HBeAg loss, this hypothesis can never be proven by the current study.
In summary, this open-label study supports the use of peginterferon switch therapy as a therapeutic strategy for patients on NA. 
